196 | Chapter 9 259. Kompas F. Farmacotherapeutisch Kompas 2024. Available from: https://www. farmacotherapeutischkompas.nl/. 260. Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32:335-44. 261. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171-89. 262. CBS. Consumentenprijzen; prijsindex 2015=100 2024. Available from: https://opendata.cbs.nl/ statline/#/CBS/nl/dataset/83131ned/table. 263. Versteegh MM, Vermeulen KM, Evers SM, De Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value in health. 2016;19(4):343-52. 264. van Leeuwen KM, Jansen AP, Muntinga ME, Bosmans JE, Westerman MJ, van Tulder MW, et al. Exploration of the content validity and feasibility of the EQ-5D-3L, ICECAP-O and ASCOT in older adults. BMC Health Services Research. 2015;15:1-10. 265. M MV, K MV, S MAAE, de Wit GA, Prenger R, E AS. Dutch Tariff for the Five-Level Version of EQ-5D. Value Health. 2016;19(4):343-52. 266. Nguyen L, Jokimäki H, Linnosmaa I, Saloniki E-C, Batchelder L, Malley J, et al. Do you prefer safety to social participation? Finnish population-based preference weights for the adult social care outcomes toolkit (ASCOT) for service users. MDM Policy & Practice. 2021;6(2):23814683211027902. 267. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Statistics in medicine. 2011;30(4):377-99. 268. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Bmj. 2009;338. 269. Ben ÂJ, van Dongen JM, El Alili M, Esser JL, Broulíková HM, Bosmans JE. Conducting trial-based economic evaluations using R: a tutorial. Pharmacoeconomics. 2023;41(11):1403-13. 270. Reckers-Droog V, van Exel J, Brouwer W. Willingness to pay for health-related quality of life gains in relation to disease severity and the age of patients. Value in Health. 2021;24(8):1182-92. 271. Kanters TA, Bouwmans CA, Van Der Linden N, Tan SS, Hakkaart-van Roijen L. Update of the Dutch manual for costing studies in health care. PloS one. 2017;12(11):e0187477. 272. Jenkyn KB, Hoch JS, Speechley M. How much are we willing to pay to prevent a fall? Cost-effectiveness of a multifactorial falls prevention program for community-dwelling older adults. Canadian Journal on Aging/La Revue canadienne du vieillissement. 2012;31(2):121-37. 273. Montero-Odasso M, van der Velde N, Martin FC, Petrovic M, Tan MP, Ryg J, et al. World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing. 2022;51(9). 274. VeiligheidNL. Feiten en cijfers valongevallen 65-plussers 2021 2021; cited 2023 21/2. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.veiligheid.nl/sites/default/ files/2022-09/Infographic%20feiten%20en%20cijfers%20valongevallen%2065-plussers%202021. pdf.
RkJQdWJsaXNoZXIy MjY0ODMw